peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
advanced age cigarette smoking hypertension (high blood pressure) obesity hyperlipidemia, e.g. hypercholesterolemia, hypertriglyceridemia, elevated lipoprotein (a) or apolipoprotein B, or decreased levels of HDL cholesterol) diabetes mellitus Sedentary lifestyle stress Other important risk factors for arterial embolism include:
== Early life and education == Berhanu Kebede was born in Addis Ababa. He graduated in 1978 with a degree in economics from Addis Ababa University and continued his studies at the Free University of Brussels, earning M.A. degrees in Development Economics (1986) and in Management and Finance (1988).
== Career == Tew was appointed the G. Willing Chair in Cancer Research at the Medical University of South Carolina from 1999 to 2004. He was the Director of the Developmental Cancer Therapeutics Program at Hollings Cancer Center from 2004 to 2019, and serves as a professor in the Department of Cell & Molecular Pharmacology at the Medical University of South Carolina. Tew has been the John C. West Chair in Cancer Research at the Medical University of South Carolina since 2004. Tew held the position of Associate Editor from 1993 to 2007 and later assumed the role of Senior Editor in the Experimental Therapeutics, Molecular Targets, and Chemical Biology Section from 2007 to 2018 for the journal Cancer Research. Concurrently, he held editorial positions including, Editor for Cellular Pharmacology, and Editor-in-Chief of Journal of Pharmacology and Experimental Therapeutics. Tew has been the Editor (USA) of Biomedicine & Pharmacotherapy since 2002 and Serial Editor for Advances in Cancer Research since 2011. Additionally, he has held appointments at InVaMet Therapeutics and the Greehey Children's Cancer Research Institute Scientific External Advisory Board since 2019.
Sources: en.wikipedia.org
== Uses == Ammonium bicarbonate is used in the food industry as a leavening agent for flat baked goods, such as cookies and crackers. It was commonly used in the home before modern-day baking powder was made available. Many baking cookbooks, especially from Scandinavian countries, may still refer to it as hartshorn or hornsalt, while it is known as "hirvensarvisuola" in Finnish, "hjortetakksalt" or "hornsalt" in Norwegian, "hjortetakssalt" in Danish, "hjorthornssalt" in Swedish, and "Hirschhornsalz" in German (lit., "salt of hart's horn"). Although there is a slight smell of ammonia during baking, this quickly dissipates, leaving no taste. It is used in, for example, Swedish "drömmar" biscuits and Danish "klejner" Christmas biscuits, and German Lebkuchen. In many cases it may be replaced with baking soda or baking powder, or a combination of both, depending on the recipe composition and leavening requirements. Compared to baking soda or potash, hartshorn has the advantage of producing more gas for the same amount of agent, and of not leaving any salty or soapy taste in the finished product, as it completely decomposes into water and gaseous products that evaporate during baking. It cannot be used for moist, bulky baked goods however, such as normal bread or cakes, since some ammonia will be trapped inside and will cause an unpleasant taste. It has been assigned E number E503 for use as a food additive in the European Union. It is commonly used as an inexpensive nitrogen fertilizer in China, but is now being phased out in favor of urea for quality and stability.
==== 1956–60 ==== In 1956, Sports Illustrated wrote that Mizell's return would help with St. Louis's pitching, a "major problem" for the Cardinals in 1955. His first outing back on April 17 was triumphant, as he allowed 12 hits but just two runs and came within one out of a complete game in a 4–2 victory over the Cincinnati Redlegs. From May 21 through June 9, he won five straight games, though he followed that up with three straight losses from June 15 through June 26. During the winning streak, in the second game of a May 27 doubleheader, he struck out 10 hitters in a 12–2 victory over the Chicago Cubs. In the first game of a doubleheader against Pittsburgh on August 23, he threw a four-hit shutout in a 3–0 victory. On September 7, 1956, facing the Redlegs, who were second to the Braves in a close pennant race, Mizell threw a two-hit shutout in a 1–0 victory. Six days later, he threw his second consecutive shutout, beating the Giants 5–0 and allowing just four hits. He had a 3.62 ERA for the Cardinals in 1956, and his 14–14 mark was reflective of St. Louis's .500 record. Mizell's 14 wins tied with Ron Kline and Hersh Freeman for 10th in the NL, but his 14 losses tied with Sam Jones, Al Worthington, and teammate Tom Poholsky for sixth. He ranked fifth in the NL with 153 strikeouts, and his mark of 6.6 strikeouts per nine innings pitched was good for third behind Jones's 8.4 and Harvey Haddix's 6.6. However, his 92 walks were third in the NL, behind Jones's 115 and Bob Buhl's 105.
== Function == Carboxypeptidase M is a membrane-bound arginine/lysine carboxypeptidase. This enzyme catalyses cleavage of C-terminal arginine or lysine residues from polypeptides. Its expression is associated with monocyte to macrophage differentiation. This encoded protein contains hydrophobic regions at the amino and carboxy termini and has 6 potential asparagine-linked glycosylation sites. The active site residues of carboxypeptidases A and B are conserved in this protein. Three alternatively spliced transcript variants encoding the same protein have been described for this gene.
Also important to Lagin has been ancient Native American rock art (petroglyphs) and European cave art "where pictures were placed and seen within nature and the natural world, not simply as representations or depictions but being part of, and kinship with, nature”. Lagin's picture-making includes nature and other photography, sand drawings, digital and physical paintings and drawings, and photographic nudes and self-portraits. His photography and art media span what he calls "the natural history of picture world"; his sand drawings using the earliest (oldest) picture-making medium (technology), and his digital photography, painting and electronic online picture presence the latest (newest) picture-making media (technologies). Most of Lagin's photography is of wilderness landscapes and seascapes, and 'intimate landscapes' of rocks and sea stones, plants, grasses, flowers, meadows, trees and forests, streams, water, sand, clouds and skies. His photos, drawings, and paintings are mostly from/of nearby wild places and home (Marin County, California). Besides many single photographs and small sets, he has created two large continuing nature photography collections, both with philosophical and spiritual themes: metaphysics (nature photos and sand drawings), and seeings (intimate nature).
Sources: en.wikipedia.org
Mike Harrington (born 1964) is an American programmer and businessman. With Gabe Newell, he is the co-founder of the video game company Valve. After the success of the first Valve game, Half-Life (1998), Harrington left Valve in 2000. In 2005, he co-founded the photo editing service Picnik.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy, or molly) is an entactogen, euphoriant, and psychostimulant of the amphetamine class. Briefly used by some psychotherapists as an adjunct to therapy, the drug became popular recreationally and, in the United States, the DEA listed MDMA as a Schedule I controlled substance, prohibiting most medical studies and applications. MDMA is known for its entactogenic properties. The stimulant effects of MDMA include hypertension, anorexia (appetite loss), euphoria, social disinhibition, insomnia (enhanced wakefulness/inability to sleep), improved energy, increased arousal, and increased perspiration, among others. Relative to catecholaminergic transmission, MDMA enhances serotonergic transmission significantly more, when compared to similar psychostimulants like amphetamine. Due to the relative safety of MDMA, some researchers such as David Nutt have criticized the scheduling level, writing a satirical article finding MDMA to be 28 times less dangerous than horseriding, a condition he termed "equasy" or "Equine Addiction Syndrome".
Nicotine replacement therapy (NRT) products, including gums, patches, and lozenges, deliver the compound in slower, lower doses that are less addictive and are used medically to help people quit smoking. Synthetic derivatives of nicotine, such as varenicline, act as partial agonists at nicotinic receptors and are also used as smoking cessation aids. Nicotine itself is not classified as a carcinogen by either the International Agency for Research on Cancer or the Surgeon General of the United States. At high doses it can cause nicotine poisoning and respiratory paralysis. Nicotine is also a known teratogen, associated with adverse developmental effects during pregnancy, and may impair adolescent neurodevelopment, though the extent of this effect in humans remains debated.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.